PRESS RELEASE published on 08/25/2025 at 08:00, 5 months 26 days ago Informations privilégiées / Autres communiqués TME Pharma lève 500 000 € via une émission obligataire pour accélérer ses activités de développement de thérapies innovantes. Nouveau soutien financier renforce la position de TME Pharma Développement Financement Émission Obligataire TME Pharma Thérapies Innovantes
BRIEF published on 07/08/2025 at 08:05, 7 months 12 days ago TME Pharma met fin à son contrat de liquidité dans le cadre d'une optimisation des coûts Contrat De Liquidité Biotechnologie Optimisation Des Coûts Refinancement TME Pharma
BRIEF published on 07/08/2025 at 08:05, 7 months 12 days ago TME Pharma Terminates Liquidity Contract Amid Cost Optimization Liquidity Contract Biotechnology Refinancing Cost Optimization TME Pharma
PRESS RELEASE published on 07/08/2025 at 08:00, 7 months 12 days ago Informations privilégiées / Autres communiqués TME Pharma annonce la résiliation du contrat de liquidité avec Invest Securities pour optimiser ses coûts et renforcer sa trésorerie. Réduction des coûts opérationnels suite à la restructuration organisationnelle Contrat De Liquidité Optimisation Des Coûts TME Pharma Restructuration Organisationnelle Développement Thérapies
PRESS RELEASE published on 07/08/2025 at 08:00, 7 months 12 days ago Inside Information / Other news releases TME Pharma terminates liquidity contract with Invest Securities to optimize costs. Improve trading volume of shares and healthy liquidity deemed contract unnecessary. Finds success in refinancing and reducing operational costs Liquidity Contract Cost Optimization Trading Volume Organizational Restructuring TME Pharma
BRIEF published on 05/21/2025 at 08:05, 8 months 30 days ago TME Pharma Enhances Financial Outlook with €1.7M Bond Commitments Strategic Partnerships Bond Issuance Clinical Programs Financial Visibility Cost Structure
BRIEF published on 05/21/2025 at 08:05, 8 months 30 days ago TME Pharma améliore ses perspectives financières avec un engagement obligataire de 1,7 million d'euros Partenariats Stratégiques Emission D'obligations Programmes Cliniques Visibilité Financière Structure Des Coûts
PRESS RELEASE published on 05/21/2025 at 08:00, 8 months 30 days ago Informations privilégiées / Autres communiqués TME Pharma, société de biotechnologie spécialisée en thérapies contre le cancer, prolonge sa visibilité financière jusqu'en mai 2026 via une émission d'obligations aux investisseurs professionnels Investisseurs Obligations Cancer Visibilité Financière TME Pharma
PRESS RELEASE published on 05/21/2025 at 08:00, 8 months 30 days ago Inside Information / Other news releases TME Pharma extends financial visibility to May 2026 by securing €1.7M financing through regular bonds with attached warrants. CEO and board show strong commitment to company's success Clinical Programs TME Pharma Financial Visibility Regular Bonds Private Warrants
BRIEF published on 04/10/2025 at 19:05, 10 months 9 days ago TME Pharma strengthens its liquidity contract with Invest Securities Liquidity Contract Oncology INVEST SECURITIES Financial Markets TME Pharma
Published on 02/20/2026 at 18:30, 16 minutes ago Sparta Updates Delay in Filing Annual Financial Statements
Published on 02/20/2026 at 15:45, 3 hours 1 minute ago Revolve Announces Closing of Initial US$10 Million Advance on Strategic Financing With Callaway
Published on 02/20/2026 at 14:30, 4 hours 16 minutes ago Norse Gold Announces Application for Reactivation to TSX-V, Private Placement Financing and Stock Options Grant
Published on 02/20/2026 at 14:08, 4 hours 38 minutes ago Datavault AI Announces Anticipated Launch of Josh Gibson Stablecoin and Josh Gibson NIL Strategies for Its Forthcoming NIL Exchange
Published on 02/20/2026 at 14:00, 4 hours 46 minutes ago Nextech3D.ai's Eventdex Platform Powers AI Matchmaking for the SBA's CT Business Matchmaker Event Featuring Government Agencies and Major Prime Contractors
Published on 02/20/2026 at 18:36, 10 minutes ago EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 18:31, 15 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/20/2026 at 18:00, 46 minutes ago Leclanché conclut un accord de financement d’un montant de CHF 16,7 millions pour soutenir ses opérations à court terme
Published on 02/20/2026 at 18:00, 46 minutes ago Leclanché Secures Financing Arrangement in the amount of CHF 16.7 million to Support Near-Term Operations
Published on 02/20/2026 at 09:28, 9 hours 18 minutes ago Déclaration du nombre d'actions composant le capital social et du nombre total de droits de vote au 31 janvier 2026
Published on 02/20/2026 at 09:28, 9 hours 18 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of January 31, 2026
